应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
BLSM Blossomhill Therapeutics Inc
盘前交易 08-18 08:06:44 EDT
16.38
+0.20
+1.24%
盘前
16.72
+0.34
+2.06%
08:03 EDT
最高
16.42
最低
16.00
成交量
19.07万
今开
16.14
昨收
16.18
日振幅
2.63%
总市值
5.02亿
流通市值
1.54亿
总股本
3,064万
成交额
308.43万
换手率
2.03%
流通股本
937.50万
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
Blossomhill Therapeutics宣布其宏环Omni-Egfr™抑制剂Bh-30643获FDA快速通道资格,用于治疗晚期EGFR C797S突变非小细胞肺癌
美股速递 · 19:01
Blossomhill Therapeutics宣布其宏环Omni-Egfr™抑制剂Bh-30643获FDA快速通道资格,用于治疗晚期EGFR C797S突变非小细胞肺癌
美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低
智通财经 · 08-08
美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低
小分子抗癌疗法开发商BlossomHill(BLSM.US)IPO定价15-17美元/股 拟筹资1.25亿美元
智通财经 · 08-04
小分子抗癌疗法开发商BlossomHill(BLSM.US)IPO定价15-17美元/股 拟筹资1.25亿美元
加载更多
公司概况
公司名称:
Blossomhill Therapeutics Inc
所属市场:
NASDAQ
上市日期:
--
主营业务:
BlossomHill Therapeutics, Inc.于2020年6月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,应用基于化学的合理药物设计方法来开发创新的小分子药物,以解决癌症治疗中未满足的重大医疗需求。其科学创始人和团队在开发创新小分子药物方面有着良好的记录,这些药物克服了现有疗法的局限性,包括多种获得批准的疗法,这些疗法已经带来了转化的患者结果。
发行价格:
--
{"stockData":{"symbol":"BLSM","market":"US","secType":"STK","nameCN":"Blossomhill Therapeutics Inc","latestPrice":16.38,"timestamp":1786996800000,"preClose":16.18,"halted":0,"volume":190677,"hourTrading":{"tag":"盘前","latestPrice":16.7171,"preClose":16.38,"latestTime":"08:03 EDT","volume":1216,"amount":20629.257599999997,"timestamp":1787054638872,"change":0.3371,"changeRate":0.02058,"amplitude":0.216728},"delay":0,"changeRate":0.012360939431396743,"floatShares":9375000,"shares":30643700,"eps":-2.444,"marketStatus":"盘前交易","change":0.2,"latestTime":"08-18 08:06:44 EDT","open":16.14,"high":16.42,"low":15.995,"amount":3084315.262554,"amplitude":0.026267,"askPrice":19,"askSize":100,"bidPrice":16.52,"bidSize":260,"shortable":3,"etf":0,"ttmEps":-2.444,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787059800000},"marketStatusCode":1,"adr":0,"listingDate":1786075200000,"exchange":"NASDAQ","adjPreClose":16.38,"preHourTrading":{"tag":"盘前","latestPrice":16.7171,"preClose":16.38,"latestTime":"08:03 EDT","volume":1216,"amount":20629.257599999997,"timestamp":1787054638872,"change":0.3371,"changeRate":0.02058,"amplitude":0.216728},"postHourTrading":{"tag":"盘后","latestPrice":16.33,"preClose":16.38,"latestTime":"19:30 EDT","volume":137,"amount":2237.46,"timestamp":1787009404590,"change":-0.05,"changeRate":-0.003053,"amplitude":0.003053},"volumeRatio":0.49631841903288193},"requestUrl":"/m/hq/s/BLSM","defaultTab":"news","newsList":[{"id":"1162137187","title":"Blossomhill Therapeutics宣布其宏环Omni-Egfr™抑制剂Bh-30643获FDA快速通道资格,用于治疗晚期EGFR C797S突变非小细胞肺癌","url":"https://stock-news.laohu8.com/highlight/detail?id=1162137187","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162137187?lang=zh_cn&edition=full","pubTime":"2026-08-18 19:01","pubTimestamp":1787050871,"startTime":"0","endTime":"0","summary":"Blossomhill Therapeutics今日宣布,美国食品药品监督管理局已授予其候选药物Bh-30643快速通道资格。该药物是一种宏环Omni-Egfr抑制剂,专为治疗携带EGFR C797S突变的晚期非小细胞肺癌患者而设计。这一资格认定意味着Bh-30643有望加速开发和审评进程,以应对当前未被满足的医疗需求。EGFR C797S突变常被视为对现有靶向治疗产生耐药性的关键机制之一,临床挑战严峻。Blossomhill Therapeutics表示,获得快速通道资格是其推进创新疗法过程中的重要里程碑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657640472","title":"美股异动 | BlossomHill Therapeutics(BLSM.US)登陆美股市场 开盘后股价小幅走低","url":"https://stock-news.laohu8.com/highlight/detail?id=2657640472","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657640472?lang=zh_cn&edition=full","pubTime":"2026-08-08 00:00","pubTimestamp":1786118400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,周五,BlossomHill Therapeutics登陆美股市场,截至发稿,该股跌超1%,报15.8美元。BlossomHill Therapeutics总部位于加州圣地亚哥,成立于2020年。该公司专注于通过识别现有治疗方法中的结构性弱点,并设计新的化合物来克服这些弱点,从而开发小分子癌症药物。公司计划于2026年第四季度与美国食品药品监督管理局举行一期临床结束会议,讨论推荐的二期临床给药方案,以及针对部分患者潜在的加速批准路径。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK4007","BK4539","LENZ","BLSM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656536749","title":"小分子抗癌疗法开发商BlossomHill(BLSM.US)IPO定价15-17美元/股 拟筹资1.25亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2656536749","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656536749?lang=zh_cn&edition=full","pubTime":"2026-08-04 16:47","pubTimestamp":1785833278,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["UUP","IPOS","BLSM","UDN"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bhtherapeutics.com","stockEarnings":[{"period":"1week","weight":0.0244},{"period":"1month","weight":0.0237},{"period":"ytd","weight":0.0237}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0395},{"period":"3month","weight":0.0531},{"period":"6month","weight":0.1259},{"period":"1year","weight":0.2008},{"period":"ytd","weight":0.1331}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"BlossomHill Therapeutics, Inc.于2020年6月22日在特拉华州注册成立。该公司是一家临床阶段的生物制药公司,应用基于化学的合理药物设计方法来开发创新的小分子药物,以解决癌症治疗中未满足的重大医疗需求。其科学创始人和团队在开发创新小分子药物方面有着良好的记录,这些药物克服了现有疗法的局限性,包括多种获得批准的疗法,这些疗法已经带来了转化的患者结果。","exchange":"NASDAQ","name":"Blossomhill Therapeutics Inc","nameEN":"Blossomhill Therapeutics Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Blossomhill Therapeutics Inc(BLSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Blossomhill Therapeutics Inc(BLSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Blossomhill Therapeutics Inc,BLSM,Blossomhill Therapeutics Inc股票,Blossomhill Therapeutics Inc股票老虎,Blossomhill Therapeutics Inc股票老虎国际,Blossomhill Therapeutics Inc行情,Blossomhill Therapeutics Inc股票行情,Blossomhill Therapeutics Inc股价,Blossomhill Therapeutics Inc股市,Blossomhill Therapeutics Inc股票价格,Blossomhill Therapeutics Inc股票交易,Blossomhill Therapeutics Inc股票购买,Blossomhill Therapeutics Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Blossomhill Therapeutics Inc(BLSM)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Blossomhill Therapeutics Inc(BLSM)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}